

# Pawel P Teterycz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1103080/publications.pdf>

Version: 2024-02-01

38  
papers

601  
citations

686830

13  
h-index

642321

23  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1106  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy of melanoma. <i>Wspolczesna Onkologia</i> , 2018, 2018, 61-67.	0.7	78
2	Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. <i>American Journal of Human Genetics</i> , 2014, 95, 590-601.	2.6	75
3	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
4	IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma. <i>Journal of Cancer</i> , 2018, 9, 998-1005.	1.2	50
5	SOX10 is as specific as S100 protein in detecting metastases of melanoma in lymph nodes and is recommended for sentinel lymph node assessment. <i>European Journal of Cancer</i> , 2020, 137, 175-182.	1.3	27
6	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	2.0	25
7	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
8	Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 2471.	1.0	22
9	Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. <i>Targeted Oncology</i> , 2019, 14, 729-742.	1.7	18
10	Feasibility and Long-Term Efficacy of PEComa Treatmentâ€”20 Years of Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2200.	1.0	15
11	Comparison of seventh and eighth edition of AJCC staging system in melanomas at locoregional stage. <i>World Journal of Surgical Oncology</i> , 2019, 17, 129.	0.8	14
12	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	0.6	14
13	Multimodal Treatment of Advanced Mucosal Melanoma in the Era of Modern Immunotherapy. <i>Cancers</i> , 2020, 12, 3131.	1.7	13
14	Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. <i>Tumori</i> , 2020, 106, 241-248.	0.6	13
15	Mutation profile of primary subungual melanomas in Caucasians. <i>Oncotarget</i> , 2020, 11, 2404-2413.	0.8	13
16	Value of planar lymphoscintigraphy (PL) versus SPECT/CT in evaluation of sentinel lymph node in trunk melanoma â€” one center, large series retrospective study. <i>Nuclear Medicine Review</i> , 2018, 21, 79-84.	0.3	13
17	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	0.9	12
18	Efficacy of Sirolimus Treatment in PEComaâ€™10 Years of Practice Perspective. <i>Journal of Clinical Medicine</i> , 2021, 10, 3705.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Blood neutrophil-to-lymphocyte ratio is associated with prognosis in advanced gastrointestinal stromal tumors treated with imatinib. <i>Tumori</i> , 2018, 104, 415-422.	0.6	11
20	Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). <i>Journal of Geriatric Oncology</i> , 2018, 9, 520-525.	0.5	10
21	Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2996.	1.0	10
22	Efficacy and Safety of Hypofractionated Preoperative Radiotherapy for Primary Locally Advanced Soft Tissue Sarcomas of Limbs or Trunk Wall. <i>Cancers</i> , 2021, 13, 2981.	1.7	10
23	High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2018, 28, 435-441.	0.6	9
24	Systemic Treatment for Advanced and Metastatic Malignant Peripheral Nerve Sheath Tumors—A Sarcoma Reference Center Experience. <i>Journal of Clinical Medicine</i> , 2020, 9, 3157.	1.0	9
25	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1949-1958.	2.0	7
26	Stereotactic radiotherapy for soft tissue and bone sarcomas: real-world evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110706.	1.4	6
27	Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors. <i>Cancers</i> , 2022, 14, 1665.	1.7	6
28	Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2168-2174.	1.1	5
29	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. <i>Cancers</i> , 2022, 14, 110.	1.7	5
30	Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in patients with advanced gastrointestinal stromal tumors treated with sunitinib after imatinib failure. <i>Oncology Letters</i> , 2019, 18, 3373-3380.	0.8	4
31	Malignant peripheral nerve sheath tumors — Outcomes and prognostic factors based on the reference center experience. <i>Surgical Oncology</i> , 2020, 35, 276-284.	0.8	4
32	Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. <i>Drugs and Aging</i> , 2021, 38, 375-396.	1.3	4
33	Treatment beyond progression with immune checkpoint inhibitors in advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21541-e21541.	0.8	1
34	The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3129.	1.0	0
35	Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10568.	1.8	0
36	Correlation of immunity-related adverse events with survival and response to anti-PD-1 treatment in patients with metastatic melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15164-e15164.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Prognostic and predictive factors for the outcomes of clear cell sarcoma (CCS) multidisciplinary treatment: The role of lymph node involvement.. Journal of Clinical Oncology, 2020, 38, e23554-e23554.	0.8	0
38	Comparison of prognostic reliability of TNM staging systems version 7/8 and SARCULATOR in primary localized liposarcomas of the extremity or trunk wall.. Journal of Clinical Oncology, 2022, 40, e23529-e23529.	0.8	0